LeadingBiotech: Boston CEO is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

René Russo, Ph.D.
CEO at Akrevia Therapeutics

Profile

René Russo, PharmD is currently Director of X4 Therapeutics following a recent completed merger of X4 with Arsanis, Inc where Dr. Russo served as President and Chief Executive Officer for 3 years. As CEO of Arsanis, Dr. Russo raised two private financing rounds and completed Arsanis’ successful IPO totaling more than $150M raised in just under 18 months. These funds enabled a global Phase 2 ICU trial of lead asset ASN100 for S. aureus in 17 countries and 65 centers as well as in-licensing of ASN500 for RSV. Prior to Arsanis, Dr. Russo spent over 11 years building key medical functions at Cubist Pharmaceuticals culminating in a $9.6B acquisition of the company by Merck. At Cubist, she contributed to the successful launch and commercialization of daptomycin (reaching over $1B in sales annually worldwide) and held various positions including Vice President, Global Medical Affairs where she led Global Medical Sciences, Clinical Microbiology, Health Economics/Outcomes Research and Field Medical Teams for a portfolio of anti-infective products. Dr. Russo played a key role in Cubist’s successful integration of two public companies, Optimer and Trius, in 2013. Prior to Cubist, Dr. Russo held several positions in R&D at Bristol-Myers Squibb contributing to the successful registration and commercialization of various anti-infectives including atazanavir and entecavir. Dr. Russo serves as a director for Life Science Cares, a rapidly growing nonprofit organization leveraging the collective impact of the Boston life sciences industry to address the cycle of poverty in the Boston area.

René Russo, Ph.D.'s Network

Agenda Sessions

  • Building Your Board: Short vs Long Term Considerations for Formation & Evolution

    , 9:00am